Controlled trial reveals that dietary heat-killed Pseudoalteromonas piscicida enhances disease resistance in olive flounder, indicating an effective low-dose alternative to live probiotics.
The Pseudoalteromonas piscicida 2515 is a potent probiotic with broad effect against Vibrio bacteria. Juvenile olive flounder (Paralichthys olivaceus) (9.04 ± 0.89 g) were used to evaluate the safety of P. piscicida 2515 (control, 106, 107, 108 and 109 CFU/g) in terms of haemolysis activity and mortality rate. To investigate the effects of P. piscicida 2515 (live and heat-killed) on the immune response, and intestinal microbiota and morphology in olive flounder (24.72 ± 2.21 g), five treatment groups, including control, L5 (live bacteria, 105 CFU/g), L7 (live bacteria, 107 CFU/g), HK5 (heat-killed bacteria, 105 CFU/g) and HK7 (heat-killed bacteria, 107 CFU/g), were set up over 35 days. The results showed that treatment with 109CFU/g live P. piscicida 2515 could lead significantly high haemolytic activity. Live- and heat-killed- P. piscicida 2515 significantly increased peroxidase (POD) and serum lysozyme (LZS) activities, while heat-killed P. piscicida 2515 increased SOD and TP. Moreover, L7 could increase expressions of IL-1β and TNF-α in kidney, whereas HK5 could raise IL-10 and TNF-α in spleen, and upregulate IL-1β in kidney. P. piscicida 2515 modulated microbiota richness (Ace and Chao1) and composition at the phylum level. In addition, supplementation of P. piscicida 2515 (live- and heat-killed) could significantly raise intestinal goblet cell number and microvilli length (p < 0.05). Particularly, fish in the treatment groups of HK5 and L7 exhibited higher survival rate against V. anguillarum infection. Therefore, P. piscicida 2515 demonstrated probiotics potency at 108 CFU/g or less based on feed supplement, and heat-killed (105 CFU/g) P. piscicida 2515 has decreased probiotic level dose and has improved the non-specific immunity, intestinal function and protected the olive flounder against V. anguillarum.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: